

# João Fernandes

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7926104/joao-fernandes-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

101  
papers

43,937  
citations

46  
h-index

104  
g-index

104  
ext. papers

58,339  
ext. citations

14.3  
avg, IF

5.37  
L-index

#	Paper	IF	Citations
101	From Sharks to Yeasts: Squalene in the Development of Vaccine Adjuvants.. <i>Pharmaceuticals</i> , <b>2022</b> , 15,	5.2	3
100	Unravelling data for rapid evidence-based response to COVID-19: a summary of the unCoVer protocol. <i>BMJ Open</i> , <b>2021</b> , 11, e055630	3	0
99	Novel Micro- and Nanocellulose-Based Delivery Systems for Liposoluble Compounds. <i>Nanomaterials</i> , <b>2021</b> , 11,	5.4	2
98	Phytosterols and Novel Triterpenes Recovered from Industrial Fermentation Coproducts Exert In Vitro Anti-Inflammatory Activity in Macrophages. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	3
97	Looking Ahead: Health Impact Assessment of Front-Of-Pack Nutrition Labelling Schema as a Public Health Measure. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	2
96	Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. <i>Lancet, The</i> , <b>2021</b> , 398, 503-521	40	29
95	Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2020</b> , 395, 709-733	40	1021
94	The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 17-30	18.8	448
93	Effectiveness of interpretive front-of-pack nutritional labelling schemes on the promotion of healthier food choices: a systematic review. <i>International Journal of Evidence-Based Healthcare</i> , <b>2020</b> , 18, 24-37	2.6	9
92	The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 42-54	18.8	184
91	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. <i>Nature Medicine</i> , <b>2020</b> , 26, 750-759	50.5	21
90	The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2019</b> , 2019, 3021785	6.7	10
89	Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2019</b> , 393, 1958-1972	40	1479
88	Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality. <i>Mediators of Inflammation</i> , <b>2019</b> , 2019, 3295725	4.3	6
87	Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients. <i>Renal Failure</i> , <b>2019</b> , 41, 662-672	2.9	3
86	The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 913-933	18.8	144
85	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. <i>Nature</i> , <b>2019</b> , 574, 353-358	58.4	87

84	The Burden of Cardiovascular Diseases Among US States, 1990-2016. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 375-389	16.2	184
83	Therapeutic application of antibody fragments in autoimmune diseases: current state and prospects. <i>Drug Discovery Today</i> , <b>2018</b> , 23, 1996-2002	8.8	29
82	Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2018</b> , 392, 1684-1735	40	483
81	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2018</b> , 392, 1736-1788	40	2850
80	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2018</b> , 392, 1923-1994	40	1964
79	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2018</b> , 392, 1789-1858	40	4524
78	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2018</b> , 392, 2091-2138	40	210
77	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2018</b> , 392, 1859-1922	40	1283
76	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2018</b> , 391, 2236-2271	40	381
75	Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 317, 165-182	27.4	957
74	Global Cardiovascular and Renal Outcomes of Reduced GFR. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2017</b> , 28, 2167-2179	12.7	127
73	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. <i>JAMA Oncology</i> , <b>2017</b> , 3, 524-548	13.4	2394
72	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2017</b> , 390, 231-266	40	352
71	Health Effects of Overweight and Obesity in 195 Countries over 25 Years. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 13-27	59.2	3027
70	Child and Adolescent Health From 1990 to 2015: Findings From the Global Burden of Diseases, Injuries, and Risk Factors 2015 Study. <i>JAMA Pediatrics</i> , <b>2017</b> , 171, 573-592	8.3	216
69	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1084-1150	40	421
68	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1260-1344	40	1152
67	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1151-1210	40	2542

66	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1211-1259	40	3432
65	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1345-1422	40	1378
64	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1423-1459	40	224
63	High Fasting Plasma Glucose, Diabetes, and Its Risk Factors in the Eastern Mediterranean Region, 1990-2013: Findings From the Global Burden of Disease Study 2013. <i>Diabetes Care</i> , <b>2017</b> , 40, 22-29	14.6	33
62	Recent Patents on Heat Shock Proteins Targeting Antibodies. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , <b>2017</b> , 12, 48-54	2.6	4
61	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. <i>Lancet HIV,the</i> , <b>2016</b> , 3, e361-e387	7.8	382
60	Recombinant human erythropoietin-induced erythropoiesis regulates hepcidin expression over iron status in the rat. <i>Blood Cells, Molecules, and Diseases</i> , <b>2016</b> , 59, 63-70	2.1	5
59	Reactivation of wild-type and mutant p53 by tryptophan-derived oxazoloisindolinone SLMP53-1, a novel anticancer small-molecule. <i>Oncotarget</i> , <b>2016</b> , 7, 4326-43	3.3	30
58	Safety profile of solid lipid nanoparticles loaded with rosmarinic acid for oral use: in vitro and animal approaches. <i>International Journal of Nanomedicine</i> , <b>2016</b> , 11, 3621-40	7.3	34
57	SP313LIVER IRON IS A MAJOR REGULATOR OF HEPcidin GENE EXPRESSION VIA BMP/SMAD PATHWAY IN A RAT MODEL OF CHRONIC RENAL FAILURE UNDER TREATMENT WITH HIGH rHuEPO DOSES. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, i194-i194	4.3	1
56	Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2016</b> , 43, 343-54	3	4
55	Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia. <i>Biochimie</i> , <b>2016</b> , 125, 150-62	4.6	7
54	Impaired renal endothelial nitric oxide synthase and reticulocyte production as modulators of hypertension induced by rHuEPO in the rat. <i>Life Sciences</i> , <b>2016</b> , 151, 147-156	6.8	4
53	Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2016</b> , 388, 1775-1812	40	476
52	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2016</b> , 388, 1603-1658	40	1216
51	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2016</b> , 388, 1459-1544	40	3525
50	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2016</b> , 388, 1545-1602	40	3801
49	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2016</b> , 388, 1725-1774	40	413

48	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2016</b> , 388, 1813-1850	4.0	302
47	Liver iron is a major regulator of hepcidin gene expression via BMP/SMAD pathway in a rat model of chronic renal failure under treatment with high rHuEPO doses. <i>BioFactors</i> , <b>2016</b> , 42, 296-306	6.1	8
46	Effects of the olive oil phenol metabolite 3,4-DHPEA-EDA <sub>2</sub> on human erythrocyte oxidative damage. <i>Food and Function</i> , <b>2015</b> , 6, 2350-6	6.1	8
45	Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model. <i>PLoS ONE</i> , <b>2015</b> , 10, e0124048	3.7	23
44	Predictors of health-related quality of life perceived by end-stage renal disease patients under online hemodiafiltration. <i>Quality of Life Research</i> , <b>2015</b> , 24, 1327-35	3.7	16
43	Effect of Aging in the Perception of Health-Related Quality of Life in End-Stage Renal Disease Patients under Online-Hemodiafiltration <b>2015</b> , 6, 17-26		4
42	Protective effect of <i>C. sativa</i> leaf extract against UV mediated-DNA damage in a human keratinocyte cell line. <i>Journal of Photochemistry and Photobiology B: Biology</i> , <b>2015</b> , 144, 28-34	6.7	28
41	Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 17,	6.3	6
40	Biocompatibility and hemocompatibility of polyvinyl alcohol hydrogel used for vascular grafting--In vitro and in vivo studies. <i>Journal of Biomedical Materials Research - Part A</i> , <b>2014</b> , 102, 4262-75	5.4	54
39	The effect of olive leaf supplementation on the constituents of blood and oxidative stability of red blood cells. <i>Journal of Functional Foods</i> , <b>2014</b> , 9, 271-279	5.1	17
38	Body fat percentage is a major determinant of total bilirubin independently of UGT1A1*28 polymorphism in young obese. <i>PLoS ONE</i> , <b>2014</b> , 9, e98467	3.7	16
37	Conversion to sirolimus ameliorates cyclosporine-induced nephropathy in the rat: focus on serum, urine, gene, and protein renal expression biomarkers. <i>BioMed Research International</i> , <b>2014</b> , 2014, 576929 <sup>3</sup>		9
36	Type of vascular access and location in online hemodiafiltration and its association with patient's perception of health-related quality of life. <i>Journal of Vascular Access</i> , <b>2014</b> , 15, 175-82	1.8	15
35	Transition from cyclosporine-induced renal dysfunction to nephrotoxicity in an in vivo rat model. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 8979-97	6.3	21
34	Iron as the key modulator of hepcidin expression in erythroid antibody-mediated hypoplasia. <i>BioMed Research International</i> , <b>2014</b> , 2014, 421304	3	4
33	Aging is Associated with Impaired Renal Function, INF-gamma Induced Inflammation and with Alterations in Iron Regulatory Proteins Gene Expression <b>2014</b> , 5, 356-65		10
32	Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide overexpression seems to be the best marker. <i>Cardiovascular Diabetology</i> , <b>2013</b> , 12, 44	8.7	50
31	The in vitro and in vivo genotoxicity of isotretinoin assessed by cytokinesis blocked micronucleus assay and comet assay. <i>Toxicology in Vitro</i> , <b>2013</b> , 27, 900-7	3.6	1

30	Cytotoxic and genotoxic effects of acitretin, alone or in combination with psoralen-ultraviolet A or narrow-band ultraviolet B-therapy in psoriatic patients. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , <b>2013</b> , 753, 42-7	3	4
29	Protective activity of hydroxytyrosol metabolites on erythrocyte oxidative-induced hemolysis. <i>Journal of Agricultural and Food Chemistry</i> , <b>2013</b> , 61, 6636-42	5.7	30
28	Effect of whey protein purity and glycerol content upon physical properties of edible films manufactured therefrom. <i>Food Hydrocolloids</i> , <b>2013</b> , 30, 110-122	10.6	282
27	Risk factors for mortality in hemodialysis patients: two-year follow-up study. <i>Disease Markers</i> , <b>2013</b> , 35, 791-8	3.2	31
26	Circulating cell-free DNA levels in hemodialysis patients and its association with inflammation, iron metabolism, and rhEPO doses. <i>Hemodialysis International</i> , <b>2013</b> , 17, 664-7	1.7	10
25	Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients. <i>Renal Failure</i> , <b>2013</b> , 35, 1392-8	2.9	6
24	Effect of composition of commercial whey protein preparations upon gelation at various pH values. <i>Food Research International</i> , <b>2012</b> , 48, 681-689	7	28
23	Antimicrobial activity of edible coatings prepared from whey protein isolate and formulated with various antimicrobial agents. <i>International Dairy Journal</i> , <b>2012</b> , 25, 132-141	3.5	42
22	Evaluation of chitoligosaccharides effect upon probiotic bacteria. <i>International Journal of Biological Macromolecules</i> , <b>2012</b> , 50, 148-52	7.9	12
21	Study of antimicrobial activity and atomic force microscopy imaging of the action mechanism of cashew tree gum. <i>Carbohydrate Polymers</i> , <b>2012</b> , 90, 270-4	10.3	38
20	Features and performance of edible films, obtained from whey protein isolate formulated with antimicrobial compounds. <i>Food Research International</i> , <b>2012</b> , 45, 351-361	7	104
19	Edible films and coatings from whey proteins: a review on formulation, and on mechanical and bioactive properties. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2012</b> , 52, 533-52	11.5	129
18	Evaluation of antimicrobial edible coatings from a whey protein isolate base to improve the shelf life of cheese. <i>Journal of Dairy Science</i> , <b>2012</b> , 95, 6282-92	4	83
17	Inhibition of bladder tumor growth by chitoooligosaccharides in an experimental carcinogenesis model. <i>Marine Drugs</i> , <b>2012</b> , 10, 2661-75	6	37
16	Major determinants of BMP-2 serum levels in hemodialysis patients. <i>Renal Failure</i> , <b>2012</b> , 34, 1355-8	2.9	2
15	Cytotoxicity and genotoxicity of chitoooligosaccharides upon lymphocytes. <i>International Journal of Biological Macromolecules</i> , <b>2011</b> , 49, 433-8	7.9	19
14	Apoptosis of peripheral CD4(+) T-lymphocytes in end-stage renal disease patients under hemodialysis and rhEPO therapies. <i>Renal Failure</i> , <b>2011</b> , 33, 138-43	2.9	21
13	Animal model of implant capsular contracture: effects of chitosan. <i>Aesthetic Surgery Journal</i> , <b>2011</b> , 31, 540-50	2.4	15

12	Powerful protective role of 3,4-dihydroxyphenylethanol-elenolic acid dialdehyde against erythrocyte oxidative-induced hemolysis. <i>Journal of Agricultural and Food Chemistry</i> , <b>2010</b> , 58, 135-40	5.7	44
11	Anti-inflammatory activity of chitooligosaccharides in vivo. <i>Marine Drugs</i> , <b>2010</b> , 8, 1763-8	6	88
10	Plant aqueous extracts: Antioxidant capacity via haemolysis and bacteriophage P22 protection. <i>Food Control</i> , <b>2010</b> , 21, 633-638	6.2	13
9	In vitro studies with $\beta$ -catalasemic-like erythrocytes and hydrogen peroxide: attention to the formation of lysis resistant erythrocytes. <i>International Journal of Laboratory Hematology</i> , <b>2010</b> , 32, 127-315	2	2
8	Antioxidant activity of chitooligosaccharides upon two biological systems: Erythrocytes and bacteriophages. <i>Carbohydrate Polymers</i> , <b>2010</b> , 79, 1101-1106	10.3	58
7	In vitro screening for anti-microbial activity of chitosans and chitooligosaccharides, aiming at potential uses in functional textiles. <i>Journal of Microbiology and Biotechnology</i> , <b>2010</b> , 20, 311-8	3.3	61
6	Effects of olive oil polyphenols on erythrocyte oxidative damage. <i>Molecular Nutrition and Food Research</i> , <b>2009</b> , 53, 609-16	5.9	82
5	Study of the antibacterial effects of chitosans on <i>Bacillus cereus</i> (and its spores) by atomic force microscopy imaging and nanoindentation. <i>Ultramicroscopy</i> , <b>2009</b> , 109, 854-60	3.1	67
4	Antimicrobial effects of chitosans and chitooligosaccharides, upon <i>Staphylococcus aureus</i> and <i>Escherichia coli</i> , in food model systems. <i>Food Microbiology</i> , <b>2008</b> , 25, 922-8	6	201
3	Effects of chitooligosaccharides on human red blood cell morphology and membrane protein structure. <i>Biomacromolecules</i> , <b>2008</b> , 9, 3346-52	6.9	46
2	Atomic force microscopy study of the antibacterial effects of chitosans on <i>Escherichia coli</i> and <i>Staphylococcus aureus</i> . <i>Ultramicroscopy</i> , <b>2008</b> , 108, 1128-34	3.1	250
1	The antimicrobial effect of wine on <i>Listeria innocua</i> in a model stomach system. <i>Food Control</i> , <b>2007</b> , 18, 1477-1483	6.2	18